For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

The UK healthcare landscape is set for a major shake-up following Prime Minister Keir Starmer’s announcement that NHS England ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Certain diabetes symptoms may contribute to hair loss, but more research is needed to explain why. Learn more about how it ...

Health associations are urging governments to ensure Canadian patients don't get caught in the crossfire of the ongoing trade ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...